Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 May;27(5):e26255.
doi: 10.1002/jia2.26255.

Urine tenofovir testing for real-time PrEP adherence feedback: a qualitative study involving transgender women in Uganda

Andrew Mujugira  1   2 , Beyonce Karungi  3 , Jackson Mugisha  1 , Agnes Nakyanzi  1 , Olivia Nampewo  1 , Faith Naddunga  1 , Brenda Kamusiime  1 , Rogers Nsubuga  1 , Kikulwe R Nyanzi  1 , Timothy R Muwonge  1 , Monique A Wyatt  4   5 , Norma C Ware  4   6 , Monica Gandhi  7 , Jessica E Haberer  8   9
Affiliations
Randomized Controlled Trial

Urine tenofovir testing for real-time PrEP adherence feedback: a qualitative study involving transgender women in Uganda

Andrew Mujugira et al. J Int AIDS Soc. 2024 May.

Abstract

Introduction: Adherence counselling with point-of-care (POC) drug-level feedback using a novel tenofovir assay may support pre-exposure prophylaxis (PrEP) adherence; however, perceptions of urine testing and its impact on adherence are not well studied. We qualitatively examined how POC tenofovir testing was experienced by transgender women (TGW) in Uganda.

Methods: Within a cluster randomized trial of peer-delivered HIV self-testing, self-sampling for sexually transmitted infections and PrEP among HIV-negative TGW showing overall low PrEP prevention-effective adherence (NCT04328025), we conducted a nested qualitative sub-study of the urine POC assay among a random sample of 30 TGW (August 2021-February 2022). TGW interviews explored: (1) experiences with POC urine tenofovir testing and (2) perceptions of PrEP adherence counselling with drug-level feedback. We used an inductive content analytic approach for analysis.

Results: Median age was 21 years (interquartile range 20-24), and 70% engaged in sex work. Four content categories describe how TGW experienced POC urine tenofovir testing: (1) Urine tenofovir testing was initially met with scepticism: Testing urine to detect PrEP initially induced anxiety, with some perceptions of being intrusive and unwarranted. With counselling, however, participants found POC testing acceptable and beneficial. (2) Alignment of urine test results and adherence behaviours: Drug-level feedback aligned with what TGW knew about their adherence. Concurrence between pill taking and tenofovir detection in urine reinforced confidence in test accuracy. (3) Interpretation of urine tenofovir results: TGW familiar with the interpretation of oral-fluid HIV self-tests knew that two lines on the test device signified positivity (presence of HIV). However, two lines on the urine test strip indicated a positive result for non-adherence (absence of tenofovir), causing confusion. Research nurses explained the difference in test interpretation to participants' satisfaction. (4) White coat dosing: Some TGW deliberately chose not to attend scheduled clinic appointments to avoid detecting their PrEP non-adherence during urine testing. They restarted PrEP before returning to clinic, a behaviour called "white coat dosing."

Conclusions: Incorporating POC urine testing into routine PrEP adherence counselling was acceptable and potentially beneficial for TGW but required attention to context. Additional research is needed to identify effective strategies for optimizing adherence monitoring and counselling for this population.

Keywords: Africa; adherence; pre‐exposure prophylaxis; qualitative; transgender women; urine tenofovir test.

PubMed Disclaimer

Conflict of interest statement

AM received a research grant from Gilead Sciences, Inc. for work unrelated to the submitted project. JEH serves as a consultant for Merck.

References

    1. Kloek M, Bulstra CA, van Noord L, Al‐Hassany L, Cowan FM, Hontelez JAC. HIV prevalence among men who have sex with men, transgender women and cisgender male sex workers in sub‐Saharan Africa: a systematic review and meta‐analysis. J Int AIDS Soc. 2022;25(11):e26022. 10.1002/jia2.26022 - DOI - PMC - PubMed
    1. Stutterheim SE, van Dijk M, Wang H, Jonas KJ. The worldwide burden of HIV in transgender individuals: an updated systematic review and meta‐analysis. PLoS One. 2021;16(12):e0260063. 10.1371/journal.pone.0260063 - DOI - PMC - PubMed
    1. Ogunbajo A, Storholm ED, Ober AJ, Bogart LM, Reback CJ, Flynn R, et al. Multilevel barriers to HIV PrEP uptake and adherence among Black and Hispanic/Latinx transgender women in Southern California. AIDS Behav. 2021;25(7):2301–2315. 10.1007/s10461-021-03159-2 - DOI - PMC - PubMed
    1. Turan JM, Elafros MA, Logie CH, Banik S, Turan B, Crockett KB, et al. Challenges and opportunities in examining and addressing intersectional stigma and health. BMC Med. 2019;17(1):7. 10.1186/s12916-018-1246-9 - DOI - PMC - PubMed
    1. Hargreaves J, Stangl A, Bond V, Hoddinott G, Krishnaratne S, Mathema H, et al. Intersecting stigmas: a framework for data collection and analysis of stigmas faced by people living with HIV and key populations. BMJ Publishing Group Ltd; 2015.

Publication types